2026-04-18T04:23:56Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1242782025-12-05T12:08:57Zcom_2072_1057col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc Cerio, Rino author Dirschka, Thomas author Dréno, Brigitte author Figueras Nart, Ignasi author Lear, John T. author Pellacani, Giovanni author Peris, Ketty author Ruiz de Casas, Andrés author 2018-09-05T07:57:46Z 2018-09-05T07:57:46Z 2017-09-01 2018-07-24T12:01:41Z Actinic keratosis (AK) is a chronic, progressive disease of the skin that has undergone long-term sun exposure. The affected areas contain visible and subclinical nonvisible sun damage resulting in epidermal keratinocyte dysplasia, known by many as ‘field cancerisation’ (1), which is prone to AKs and sun-related skin cancer (2). Thus, visible AKs are clinical biomarkers for a photo-damaged field with subclinical damage associated with the unpredictable risk of progression to invasive squamous cell carcinoma (iSCC) (3). The aim of this multiexpert opinion article is to provide a discussion succinctly highlighting the clinical gaps for optimal management of AK: the lack of a universal definition and the need for a standardised grade assessment of AK/field cancerisation that also takes into account individual risk. Tumors Malalties de la pell Skin diseases Actinic Keratosis, a Chronic, Progressive Disease: Understanding Clinical Gaps to Optimise Patient Management